Lazard Capital Markets upgraded shares of Regeneron Pharmaceuticals (NASDAQ: REGN) from a neutral rating to a buy rating in a report issued on Friday, Stock Ratings Network.com reports. They currently have $298.00 target price on the stock.
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) opened at 268.64 on Friday. Regeneron Pharmaceuticals has a 52 week low of $117.80 and a 52 week high of $283.99. The stock’s 50-day moving average is currently $238.1. The company has a market cap of $26.025 billion and a P/E ratio of 35.92.
REGN has been the subject of a number of other recent research reports. Analysts at Lazard Ltd. upgraded shares of Regeneron Pharmaceuticals from a neutral rating to a buy rating in a research note to investors on Friday. Separately, analysts at TheStreet reiterated a buy rating on shares of Regeneron Pharmaceuticals in a research note to investors on Thursday, July 11th. Finally, analysts at Thomson Reuters/Verus downgraded shares of Regeneron Pharmaceuticals from a hold rating to a sell rating in a research note to investors on Monday, July 1st.
One research analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have assigned a buy rating to the company. The stock has an average rating of Buy and an average price target of $253.94.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.